The present study suggests that cadherin-switch in the sense of E-CAD loss and N-CAD de novo expression in the invasion front of re-OSCC seems to be an inherent histological hallmark that doesn’t change within the same tumor from primary manifestation to recurrence, regardless of the kind of adjuvant treatment for the primary tumor. Here, CDH17 is linked to neoplasm.